ABSTRACT
OBJECTIVES: The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy. METHODS: Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment. RESULTS: Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of 5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%), completed HCV treatment (1598 of 3876; 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001). CONCLUSIONS: In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.
Subject(s)
Antiviral Agents/therapeutic use , Continuity of Patient Care/standards , HIV Infections/drug therapy , Hepatitis C/drug therapy , Adult , Europe , Female , Humans , Male , Middle Aged , Young AdultABSTRACT
BACKGROUND: HIV-1 viral load testing is now recommended by the World Health Organization for every patient receiving antiretroviral therapy (ART). OBJECTIVES: The objective of this study is to evaluate the performance of commercial assays for their ability to quantify HIV-1 strains currently circulating in France. STUDY DESIGN: The performances of the Generic HIV-RNA assay from Biocentric were compared to those of the Roche CAP/CTM v1.5, Roche CAP/CTM v2.0 and Abbott m2000 RealTime HIV-1 assays. A total of 1885 HIV-1 plasma samples were tested, including 684 samples from patients included in the ANRS-Primo Cohort. RESULTS: We found a good concordance of quantification between the Roche v2.0 and the Biocentric assays, both of which were superior to the Roche v1.5 assay. We show moderate agreement between techniques; however, CRF02_AG strains and undetermined viruses were underestimated when quantified with the Roche CAP/CTM v2.0. In contrast, a comparison of the Biocentric and Abbott assay results showed strong agreement between assays, indicating that both are well suited for quantification of CRF02_AG strains. Moreover, a 2% underestimation of the B subtypes was observed with the Biocentric assay. CONCLUSIONS: These results have implications for viral load monitoring in Western Africa, where CRF02_AG strains are highly prevalent. Closer epidemiological surveillance and evaluation of commercial assays are still necessary to better evaluate the impact of the genetic evolution of circulating viruses on HIV-RNA quantification in the regions most affected by the HIV-1 epidemic.
Subject(s)
Clinical Laboratory Techniques/methods , HIV Infections/diagnosis , HIV-1/classification , RNA, Viral/blood , Viral Load/methods , Cohort Studies , France , HIV Infections/virology , HIV Seropositivity/diagnosis , Humans , Mass Screening , RNA, Viral/genetics , Sensitivity and SpecificityABSTRACT
OBJECTIVES: B-cell dysfunction and activation are thought to contribute to lymphoma development in HIV-positive people; however, the mechanisms are not well understood. We investigated levels of several markers of B-cell dysfunction [free light chain (FLC)-κ, FLC-λ, immunoglobulin G (IgG), IgA, IgM and IgD] prior to lymphoma diagnosis in HIV-positive people. METHODS: A nested matched case-control study was carried out within the EuroSIDA cohort, including 73 HIV-positive people with lymphoma and 143 HIV-positive lymphoma-free controls. Markers of B-cell dysfunction were measured in prospectively stored serial plasma samples collected before the diagnosis of lymphoma (or selection date in controls). Marker levels ≤ 2 and > 2 years prior to diagnosis were investigated. RESULTS: Two-fold higher levels of FLC-κ [odds ratio (OR) 1.84; 95% confidence interval (CI) 1.19, 2.84], FLC-λ (OR 2.15; 95% CI 1.34, 3.46), IgG (OR 3.05; 95% CI 1.41, 6.59) and IgM (OR 1.46; 95% CI 1.01, 2.11) were associated with increased risk of lymphoma > 2 years prior to diagnosis, but not ≤ 2 years prior. Despite significant associations > 2 years prior to diagnosis, the predictive accuracy of each marker was poor, with FLC-λ emerging as the strongest candidate with a c-statistic of 0.67 (95% CI 0.58, 0.76). CONCLUSIONS: FLC-κ, FLC-λ and IgG levels were higher > 2 years before lymphoma diagnosis, suggesting that B-cell dysfunction occurs many years prior to lymphoma development. However, the predictive value of each marker was low and they are unlikely candidates for risk assessment for targeted intervention.
Subject(s)
B-Lymphocytes/immunology , B-Lymphocytes/pathology , HIV Infections/complications , Lymphocyte Activation , Lymphoma/pathology , Adult , Case-Control Studies , Female , Humans , Immunoglobulin G/blood , Immunoglobulin Light Chains/blood , Male , Middle Aged , Prospective StudiesABSTRACT
STUDY QUESTION: Are antiretroviral therapies associated with semen alterations in HIV-infected men? SUMMARY ANSWER: Antiretroviral regimens that included the non-nucleosidic reverse transcriptase inhibitor efavirenz were associated with a significant impairment of sperm motility, whereas regimens without efavirenz were not associated with significant semen changes. WHAT IS KNOWN ALREADY: Semen alterations including decreased ejaculate volume and sperm motility have been reported in HIV-infected men. The hypothesis ascribing reduced sperm motility to damages induced in sperm mitochondria by nucleosidic (or nucleotidic) reverse transcriptase inhibitors (NRTIs) has not been confirmed in HIV-infected patients and the effects of antiretroviral treatments on semen parameters remain unclear. STUDY DESIGN, SIZE, DURATION: This case-control study compared semen characteristics across 378 HIV-1 infected patients receiving different antiretroviral regimens or never treated by antiretroviral drugs, in whom an initial semen analysis was done between 2001 and 2007. PARTICIPANTS/MATERIALS, SETTING, METHODS: The patients were partners from serodiscordant couples requesting medical assistance to procreate safely. Their status with regard to antiretroviral therapy at the time of semen analysis was categorized as follows: 1/ never treated patients (n = 66); 2/ patients receiving NRTIs only (n = 49); 3/ patients receiving a NRTIs + protease inhibitor (PI) regimen (n = 144); 4/ patients receiving a NRTIs + non-nucleosidic reverse transcriptase inhibitor (NNRTI) regimen (n = 119). Semen parameters were assessed through standard semen analysis. Additional analyses included measurement of sperm motion parameters using computer-assisted semen analysis, seminal bacteriological analysis, seminal biochemical markers and testosterone plasmatic levels. All analyses were performed in the Cochin academic hospital. The data were analyzed through multivariate analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Sperm motility was the only semen parameter which significantly varied according to treatment status. The median percentage of rapid spermatozoa was 5% in the group of patients receiving a regimen including efavirenz versus 20% in the other groups (P < 0.0001). Accordingly, sperm velocity was reduced by about 30% in this group (P < 0.0001). The role of chance was minimized by the strict definition and the size of the study population, which included a large enough group of never treated patients, the controlled conditions of semen collection and analysis, the multivariate analysis, the specificity and the high significance level of the observed differences. LIMITATIONS, REASONS FOR CAUTION: The design of the study did not allow demonstrating a causal link between exposure to efavirenz and sperm motility. WIDER IMPLICATIONS OF THE FINDINGS: As efavirenz is widely used in current antiretroviral therapy, these findings may concern many HIV-infected men wishing to have children. This justifies further assessment of the consequences on fertility of the exposure to efavirenz. Moreover, the possibility of common cellular impacts underlying adverse effects of efavirenz in sperm cells and neurons deserved investigation. STUDY FUNDING/COMPETING INTERESTS: No external funding was used for this study. None of the authors has any conflict of interest to declare.
Subject(s)
Benzoxazines/adverse effects , HIV Infections/drug therapy , Infertility, Male/chemically induced , Reverse Transcriptase Inhibitors/adverse effects , Sperm Motility/drug effects , Adult , Alkynes , Benzoxazines/pharmacology , Benzoxazines/therapeutic use , Case-Control Studies , Cyclopropanes , HIV Infections/physiopathology , Humans , Infertility, Male/physiopathology , Male , Reverse Transcriptase Inhibitors/pharmacology , Reverse Transcriptase Inhibitors/therapeutic use , Semen AnalysisABSTRACT
BACKGROUND: We assessed how family physicians screened for HIV infection in Paris, in 2013 and whether their practice had changed after publication of the HAS (French National Authority for Health) recommendation for systematic screening. METHOD: Family practitioners (FPs) in Paris answered a questionnaire by e-mail or regular mail from January to April 2013. The statistical analysis was performed with the Chi(2) test. RESULTS: Four hundred and seven FPs answered (77.8% response rate). FPs did not always identify risk cases: 78% in case of sexually transmitted infection, but 32% for partner change, 39% for patients from a highly HIV endemic country, and 21% for sexually active teenagers or adults. Practices differed according to districts. FPs in the 1st and in the Northeastern Paris districts detected risk cases for HIV more often than their colleagues, and they used screening more often, with, consequently, more frequently positive results. The screening strategies also differed according to the FPs' demographic characteristics and their type of practice: young (P = 0.0002) female (P = 0.02) FPs working in "sector 1 (patients fully reimbursed)" (P = 8.10(-5)) prescribed more HIV blood tests. Surprisingly, only 45% of FPs was aware of the recent recommendation for systematic screening of HIV. CONCLUSION: The Paris FP screening practices differ according to demographic characteristics, place, and type of practice. Screening practices have not changed since the publication of the new screening strategy.
Subject(s)
AIDS Serodiagnosis/statistics & numerical data , Guideline Adherence/statistics & numerical data , HIV Infections/diagnosis , Mass Screening/methods , Physicians, Family/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Adolescent , Adult , Anti-HIV Agents/therapeutic use , Attitude of Health Personnel , Emigrants and Immigrants , Faculty, Medical , Female , HIV Infections/drug therapy , HIV Infections/epidemiology , Health Care Surveys , Humans , Male , Mass Screening/statistics & numerical data , Middle Aged , Paris , Practice Guidelines as Topic , Referral and Consultation/statistics & numerical data , Risk Factors , Sexual Behavior , Sexually Transmitted Diseases/epidemiology , Surveys and Questionnaires , Urban PopulationABSTRACT
Optimal staging and evaluation of residual lesions of invasive fungal infections (IFIs) are major challenges in the immunocompromised host. Preliminary data have suggested that [¹8F]fluorodeoxyglucose ([¹8F]FDG) uptake may be observed in the course of active invasive fungal infections. The aim of this study was to assess the role of positron emission tomography with [¹8F]FDG ([¹8F]FDG-PET) in the diagnosis and staging of IFI. A prospective monocentric study evaluating [¹8F]FDG-PET in 30 consecutive adults and children with European Organization for Research and Treatment of Cancer/Mycoses Study Group probable or proven IFI was performed. Twenty males and ten females (median age, 45 years (range 6-7 years)) were enrolled. Twenty-six were immunocompromised, as follows: haematological malignancy (18) with allogeneic stem cell transplantation (16/18), solid tumour (three), solid organ transplantation (two), diabetes mellitus (two) and cystic fibrosis (one). IFIs were acute invasive aspergillosis (ten), chronic disseminated candidiasis (ten), zygomycosis (two), black grains eumycetoma (two), pulmonary Histoplasma capsulatum var. capsulatum histoplasmosis (two), and Phomopsis sp. osteoarthritis, Scedosporium apiospermum and Candida krusei spondylodiscitis, and acute pulmonary coccidioidomycosis in one case each. An increased uptake of [¹8F]FDG was observed in all areas previously identified by computed tomography and/or magnetic resonance imaging to be involved by IFI. In 4/10 chronic disseminated candidiasis cases, [¹8F]FDG-PET revealed small splenic abscesses that were unapparent on the corresponding computed tomography scan. [¹8F]FDG uptake disappeared after 6 months of antifungal therapy in three patients with chronic disseminated candidiasis for whom the [¹8F]FDG-PET was performed to assess the evolution of the disease. [¹8F]FDG-PET could potentially be useful for the initial diagnosis and staging of IFI. Whether or not [¹8F]FDG-PET might be useful for assessing the optimal duration of IFI therapy should now be assessed in a specific prospective study.
Subject(s)
Fluorodeoxyglucose F18 , Mycoses/diagnostic imaging , Radiopharmaceuticals , Adolescent , Adult , Aged , Child , Female , Humans , Male , Middle Aged , Mycoses/pathology , Positron-Emission Tomography , Prospective Studies , Whole Body Imaging , Young AdultABSTRACT
Kidney transplantation is now considered as a reasonable option for HIV-infected patients with end-stage renal disease. We describe here a retrospective study conducted in five transplantation centers in Paris. Twenty-seven patients were included. Immunosuppressive protocol associated an induction therapy and a long-term treatment combining mycophenolate mofetil, steroids and either tacrolimus or cyclosporine. All the patients had protocol biopsies at 3 months and 1 year. Patient's survival was 100% at 1 year and 98% at 2 years. Graft survival at 1 and 2 years is 98% and 96% at 1 and 2 years, respectively. The mean glomerular filteration rate values at 12 and 24 months were 60.6 mL/min/1.73 m² (range 23-98) and 65.4 mL/min/1.73 m² (range 24-110), respectively. Acute cellular rejection was diagnosed in four cases (15%). Because of high trough levels of calcineurin inhibitor, protease-inhibitor therapies were withdrawn in 11 cases. HIV disease progression was not observed. One patient developed B-cell lymphoma. In conclusion, our study confirms the safety of renal transplantation in HIV-infected patients with few adverse events and a low incidence of acute rejection.
Subject(s)
HIV Infections/complications , Kidney Failure, Chronic/surgery , Kidney Transplantation , Adult , Cyclosporine/administration & dosage , Female , Graft Rejection/epidemiology , Graft Survival , HIV Infections/surgery , Humans , Immunosuppressive Agents/administration & dosage , Kidney Failure, Chronic/etiology , Kidney Transplantation/adverse effects , Male , Middle Aged , Paris/epidemiology , Retrospective Studies , Tacrolimus/administration & dosageABSTRACT
BACKGROUND: Darunavir (DRV) is the latest protease inhibitor (PI) to be approved for antiretroviral-naive and -experienced HIV-infected patients. OBJECTIVES: We examined virologic and immunologic outcomes of highly antiretroviral-experienced patients with triple-class drug resistance receiving DRV/r-based regimens, and attempted to identify factors predictive of virologic success. STUDY DESIGN: We studied patients beginning a ritonavir-boosted DRV (DRV/r 600/100mg twice daily)-containing regimen. Virologic success was defined as plasma viral load (pVL)<50copies/ml at week 36. RESULTS: We studied 62 patients with very severe immunodeficiency (CDC stage C in 69% of cases; median CD4 cell nadir 12/mm(3)). They had previously received a median of four PI and had extensive PI resistance, with a median of three major PI and two DRV resistance mutations. The baseline median pVL and CD4 cell count values were 4.6log(10) and 150/mm(3). At week 36, pVL had fallen by 2.6log(10) and the CD4 cell count had risen by 123cells/mm(3). The virologic success rate was 55% overall, and was improved by concomitant first use of enfuvirtide (67%), raltegravir (69%) or etravirine (75%). Virologic success was independently associated with fewer major PI mutations, previous tipranavir exposure, and concomitant first use of enfuvirtide or raltegravir. CONCLUSIONS: In these highly antiretroviral-experienced patients with triple-class drug resistance, virologic success of DRV-containing regimens was mainly associated with the use of new drug classes and/or fully active drugs. Interestingly, previous tipranavir failure did not undermine the efficacy of DRV, confirming the low level of cross-resistance and, probably, distinct resistance profiles between DRV and tipranavir.
Subject(s)
Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Drug Resistance, Viral , HIV Infections/drug therapy , HIV-1/drug effects , Ritonavir/therapeutic use , Sulfonamides/therapeutic use , Adult , CD4 Lymphocyte Count , Darunavir , Female , Humans , Male , Middle Aged , Treatment Outcome , Viral LoadSubject(s)
Rickettsia Infections/diagnosis , Rickettsia Infections/microbiology , Rickettsia/isolation & purification , Tick-Borne Diseases/diagnosis , Tick-Borne Diseases/microbiology , Ticks/microbiology , Animals , Antibodies, Bacterial/blood , Bacterial Proteins/genetics , Citrate (si)-Synthase/genetics , DNA, Bacterial/genetics , DNA, Bacterial/isolation & purification , Female , Fluorescent Antibody Technique, Indirect , France , Humans , Middle Aged , Polymerase Chain Reaction , Sequence Homology, Amino AcidABSTRACT
Rhodococcus equi is a bacterial pathogen of domestic animals that can infect immunocompromised patients, especially those with impaired cellular immunity, such as transplant recipients. No standard treatment has been established, but therapy must be prolonged, as relapses are common and can occur at the initial site or distant locations. Here we report a case of R. equi-associated pulmonary abscess in a renal transplant recipient successfully treated with a combination of carbapenem and teicoplanin. This combination was shown to be synergistic. It has minimal side effects in transplant recipients and appears to be an effective initial treatment for this severe infection.
Subject(s)
Actinomycetales Infections/drug therapy , Anti-Bacterial Agents/therapeutic use , Carbapenems/therapeutic use , Kidney Transplantation/adverse effects , Pneumonia, Bacterial/drug therapy , Rhodococcus equi/drug effects , Teicoplanin/therapeutic use , Actinomycetales Infections/microbiology , Drug Synergism , Drug Therapy, Combination , Humans , Lung Abscess/drug therapy , Lung Abscess/microbiology , Male , Middle Aged , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/physiopathology , Severity of Illness Index , Treatment OutcomeABSTRACT
An ongoing outbreak of lymphogranuloma venereum (LGV) L2b proctitis, predominantly in HIV-positive men who have sex with men (MSM), has been reported in industrialised countries. A case of reactive arthritis after L2b proctitis is described. This case expands the spectrum of severe complications related to LGV L2b proctitis. Since this infection may be asymptomatic, this organism should be screened for in HIV-positive MSM with symptoms consistent with reactive arthritis.
Subject(s)
Arthritis, Reactive/etiology , Chlamydia trachomatis/isolation & purification , Homosexuality, Male , Lymphogranuloma Venereum/complications , Proctitis/complications , Adult , Chlamydia trachomatis/genetics , HIV Infections/complications , HIV-1 , Humans , Lymphogranuloma Venereum/microbiology , Male , Proctitis/microbiologyABSTRACT
INTRODUCTION: There are insufficient data regarding the efficacy and safety of vaccination in patients with auto-immune disease (AID) and/or drug-related immune deficiency (DRID). The objective of this study was to obtain professional agreement on vaccine practices in these patients. METHODS: A Delphi survey was carried out with physicians recognised for their expertise in vaccinology and/or the caring for adult patients with AID and/or DRID. For each proposed vaccination practice, the experts' opinion and level of agreement were evaluated. RESULTS: The proposals relating to patients with AID specified: the absence of risk of AID relapse following vaccination; the possibility of administering live virus vaccines (LVV) to patients not receiving immunosuppressants; the pertinence of determining protective antibody titre before vaccination; the absence of need for specific monitoring following the vaccination. The proposals relating to patients with DRID specified that a 3-6 month delay is needed between the end of these treatments and the vaccination with LVV. There is no contraindication to administering LVV in patients receiving systemic corticosteroids prescribed for less than two weeks, regardless of their dose, or at a daily dose not exceeding 10mg of prednisone, if this involves prolonged treatment. Out of 14 proposals, the level of agreement between the experts was "very good" for eleven, and "good" for the remaining three. CONCLUSION: Proposals for vaccine practices in patients with AID and/or DRID should aid with decision-making in daily medical practice and provide better vaccine coverage for these patients.
Subject(s)
Autoimmune Diseases/immunology , Autoimmune Diseases/therapy , Immunologic Deficiency Syndromes/immunology , Immunologic Deficiency Syndromes/therapy , Vaccination/adverse effects , Vaccination/methods , Adrenal Cortex Hormones/adverse effects , Adult , Antineoplastic Agents/adverse effects , Expert Testimony , Humans , Immunologic Deficiency Syndromes/chemically induced , Immunosuppression Therapy/adverse effects , Immunosuppressive Agents/adverse effects , Surveys and Questionnaires , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Vaccination/statistics & numerical dataABSTRACT
Microsporidiosis first came to prominence as an opportunistic infection in patients with acquired immunodeficiency syndrome. Microsporidia are now emerging pathogens responsible for severe diarrhea during solid organ transplantation. Two main clinical entities can be identified: infection by Enterocytozoon bieneusi, causing diarrhea with limited treatment options; and infection by Encephalitozoon intestinalis, which may disseminate and usually responds to albendazole treatment. We describe here 2 cases of microsporidiosis caused by E. bieneusi in a renal and a liver transplant recipient, respectively, in whom complete clinical efficacy of a short course of fumagillin therapy was obtained. Long-term microbiological eradication was assessed using classical methods and monitored using a real-time quantitative polymerase chain reaction-based method. Both patients experienced drug-induced thrombocytopenia, which resolved after withdrawal of the treatment. We also review the 18 other previously reported cases of microsporidiosis in transplant recipients. In case of persistent diarrhea in solid organ transplant patients, microsporidiosis should be considered. Based on the present experience, treating E. bieneusi infection with 7 days of fumagillin therapy is adequate to eradicate E. bieneusi in this context.
Subject(s)
Cyclohexanes/therapeutic use , Enterocytozoon/drug effects , Fatty Acids, Unsaturated/therapeutic use , Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Microsporidiosis/drug therapy , Animals , Humans , Male , Microsporidiosis/microbiology , Middle Aged , Sesquiterpenes/therapeutic use , Treatment OutcomeABSTRACT
Coccidioidomycosis is an endemic mycosis in the southwest of United States resulting from the inhalation of arthrospores present in desert soil. The authors present a case of uncomplicated pulmonary coccidioidomycosis in a healthy woman, acquired during a recent trip to California. The initial clinical presentation first suggested a diagnosis of community-acquired pneumonia, then of tuberculosis. The diagnosis was finally reached with blood tests and mycological culture of broncho-alveolar lavage fluid. The final identification of Coccidioides immitis was made by molecular analysis. Clinical resolution of the infection was obtained after three months of posaconazole treatment. Coccidioidomycosis is a major cause of pneumonia. Its diagnosis requires specific investigation such as mycological culture, histology, blood tests and molecular biology helps to identify the species. The progression of the disease as well as the associated immunocellular deficit are strictly correlated with the onset of complications and late relapses despite an adequate initial treatment using antifungal molecules and/or surgery.
Subject(s)
Coccidioidomycosis/diagnosis , Antifungal Agents/therapeutic use , Bronchoalveolar Lavage Fluid/microbiology , Coccidioides/drug effects , Coccidioides/isolation & purification , Coccidioidomycosis/drug therapy , Diagnosis, Differential , Female , France , Humans , Middle Aged , TravelABSTRACT
Pasteurella are commensal gram-negative bacteria isolated from the oral cavity of many domesticated animals. Most human infections occur post animal bite or scratch injury resulting in local cutaneous infection; however, case reports suggest that transmission may occur via animal secretions. Pasteurella species can be associated with serious systemic infections particularly in those with underlying disease and in the immunocompromised. We present a case of invasive Pasteurella multocida sinusitis in an immunocompromised renal transplant patient most likely acquired from a pet dog through direct mucosal inoculation via licking.
Subject(s)
Dogs/microbiology , Kidney Transplantation/adverse effects , Pasteurella Infections/etiology , Pasteurella multocida , Sinusitis/etiology , Adult , Animals , Animals, Domestic , Female , Humans , Immunocompromised HostABSTRACT
Immune reconstitution inflammatory syndrome (IRIS) has rarely been described in the course of disseminated cryptococcosis in solid organ transplant recipients. We report here the case of a renal transplant recipient who developed severe cellulitis in the context of Cryptococcus neoformans-associated IRIS while undergoing reduction of his immunosuppressive therapy. IRIS appeared concomitantly with a dramatic increase of blood CD4+ T cells (94-460/mm(3)) and required the administration of a short-term steroid therapy to resolve.
Subject(s)
Cellulitis/diagnosis , Cellulitis/microbiology , Cryptococcosis/complications , Cryptococcosis/diagnosis , Immune Reconstitution Inflammatory Syndrome/complications , Immune Reconstitution Inflammatory Syndrome/diagnosis , Kidney Transplantation/immunology , Adrenal Cortex Hormones/therapeutic use , Antifungal Agents/therapeutic use , Cellulitis/immunology , Cryptococcosis/immunology , Cryptococcus neoformans/immunology , Humans , Immune Reconstitution Inflammatory Syndrome/immunology , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Opportunistic Infections/complications , Opportunistic Infections/diagnosis , Opportunistic Infections/immunology , Transplantation, HomologousSubject(s)
Continuity of Patient Care , HIV Infections/therapy , Adolescent , Adult , Aging , Attitude to Health , Child , Female , HIV Infections/psychology , HIV Infections/transmission , Humans , Infant, Newborn , Infectious Disease Transmission, Vertical , Pregnancy , Pregnancy Complications/virologyABSTRACT
The present study describes a case of pulmonary arterial hypertension (PAH) associated with multicentric Castleman's disease in a patient infected with HIV type 1 and human herpes virus 8. Therapy included highly active antiretroviral therapy, warfarin, diuretics, continuous i.v. epoprostenol and 12-monthly pulses of cyclophosphamide. The patient's condition improved dramatically with complete reversibility of PAH, allowing weaning of continuous i.v. epoprostenol therapy. After 5 yrs, both Castleman's disease and PAH have not relapsed. This supports the hypothesis that control of inflammation and retroviral replication may be of interest in the context of PAH, complicating the course of an inflammatory condition associated with viral infection. In conclusion, further studies should help in characterising the best candidates for anti-inflammatory treatment in the setting of pulmonary arterial hypertension.